Regulation of TP53 Expression and Degradation

Pathway network for the Regulation of TP53 Expression and Degradation SuperPath

Sources:

Reactome

Pathways in the Regulation of TP53 Expression and Degradation SuperPath

#	Name	Source	Genes
1	Regulation of TP53 Expression and Degradation	Reactome	AKT1 AKT2 AKT3 ATM CCNA1 CCNA2 CCNG1 CDK1 CDK2 CDKN2A CHEK2 DAXX MAPKAP1 MDM2 MDM4 MLST8 MTOR PDPK1 PHF20 PPP2CA PPP2CB PPP2R1A PPP2R1B PPP2R5C PRDM1 PRR5 RFFL RICTOR RNF34 RPS27A SGK1 TP53 UBA52 UBB UBC USP7 (see all 36) (see less)
2	Regulation of TP53 Degradation	Reactome	AKT1 AKT2 AKT3 ATM CCNA1 CCNA2 CCNG1 CDK1 CDK2 CDKN2A CHEK2 DAXX MAPKAP1 MDM2 MDM4 MLST8 MTOR PDPK1 PHF20 PPP2CA PPP2CB PPP2R1A PPP2R1B PPP2R5C PRR5 RFFL RICTOR RNF34 RPS27A SGK1 TP53 UBA52 UBB UBC USP7 (see all 35) (see less)
3	Regulation of TP53 Expression	Reactome	PRDM1 TP53

Gene overlap in member pathways for Regulation of TP53 Expression and Degradation SuperPath

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	TP53	Tumor Protein P53	Protein Coding	3
2	AKT3	AKT Serine/Threonine Kinase 3	Protein Coding	2
3	CDK2	Cyclin Dependent Kinase 2	Protein Coding	2
4	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	2
5	CHEK2	Checkpoint Kinase 2	Protein Coding	2
6	RFFL	Ring Finger And FYVE Like Domain Containing E3 Ubiquitin Protein Ligase	Protein Coding	2
7	DAXX	Death Domain Associated Protein	Protein Coding	2
8	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	2
9	AKT2	AKT Serine/Threonine Kinase 2	Protein Coding	2
10	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	2
11	RICTOR	RPTOR Independent Companion Of MTOR Complex 2	Protein Coding	2
12	MDM2	MDM2 Proto-Oncogene	Protein Coding	2
13	MDM4	MDM4 Regulator Of P53	Protein Coding	2
14	ATM	ATM Serine/Threonine Kinase	Protein Coding	2
15	PHF20	PHD Finger Protein 20	Protein Coding	2
16	PDPK1	3-Phosphoinositide Dependent Protein Kinase 1	Protein Coding	2
17	PPP2CA	Protein Phosphatase 2 Catalytic Subunit Alpha	Protein Coding	2
18	PPP2CB	Protein Phosphatase 2 Catalytic Subunit Beta	Protein Coding	2
19	PPP2R1A	Protein Phosphatase 2 Scaffold Subunit Aalpha	Protein Coding	2
20	PPP2R1B	Protein Phosphatase 2 Scaffold Subunit Abeta	Protein Coding	2
21	PPP2R5C	Protein Phosphatase 2 Regulatory Subunit B''Gamma	Protein Coding	2
22	PRR5	Proline Rich 5	Protein Coding	2
23	RPS27A	Ribosomal Protein S27a	Protein Coding	2
24	PRDM1	PR/SET Domain 1	Protein Coding	2
25	MLST8	MTOR Associated Protein MLST8	Protein Coding	2
26	SGK1	Serum/Glucocorticoid Regulated Kinase 1	Protein Coding	2
27	UBA52	Ubiquitin A-52 Residue Ribosomal Protein Fusion Product 1	Protein Coding	2
28	UBB	Ubiquitin B	Protein Coding	2
29	UBC	Ubiquitin C	Protein Coding	2
30	USP7	Ubiquitin Specific Peptidase 7	Protein Coding	2
31	MAPKAP1	MAPK Associated Protein 1	Protein Coding	2
32	RNF34	Ring Finger Protein 34	Protein Coding	2
33	CCNA2	Cyclin A2	Protein Coding	2
34	CCNA1	Cyclin A1	Protein Coding	2
35	CCNG1	Cyclin G1	Protein Coding	2
36	CDK1	Cyclin Dependent Kinase 1	Protein Coding	2

Disorders associated with Regulation of TP53 Expression and Degradation SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Li-fraumeni syndrome	Enrichment	CDKN2A, CHEK2, MDM2, TP53	9.23
2	Pancreatic cancer	Enrichment	ATM, CDKN2A, CHEK2, TP53	6.34
3	Gastric cancer	Enrichment	ATM, CDKN2A, CHEK2, TP53	5.37
4	Hereditary breast carcinoma	Enrichment	AKT1, ATM, CHEK2, TP53	5.33
5	Ovarian cancer	Enrichment	AKT1, ATM, CDKN2A, CHEK2, TP53	5.25
6	Li-fraumeni syndrome 1	Enrichment	CHEK2, TP53	5.19
7	Sarcoma	Enrichment	CHEK2, TP53	5.19
8	Osteogenic sarcoma	Enrichment	CHEK2, TP53	4.71
9	Adenocarcinoma	Enrichment	ATM, TP53	4.71
10	Bone osteosarcoma	Enrichment	CHEK2, TP53	4.71
11	Breast cancer	Enrichment	AKT1, ATM, CHEK2, TP53	4.40
12	Bladder cancer	Enrichment	ATM, CDKN2A, TP53	4.26
13	Prostate cancer	Enrichment	ATM, CHEK2, TP53	4.26
14	Hemimegalencephaly	Enrichment	AKT3, MTOR	4.19
15	Colorectal cancer	Enrichment	AKT1, ATM, CHEK2, TP53	4.15
16	Adrenocortical carcinoma	Enrichment	CDKN2A, TP53	4.02
17	Breast adenocarcinoma	Enrichment	AKT1, TP53	4.02
18	Renal cell carcinoma, papillary, 1	Enrichment	ATM, MTOR	3.87
19	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	Enrichment	CDKN2A, TP53	3.87
20	Bone marrow failure syndrome 5	Enrichment	TP53	3.83
21	Papilloma of choroid plexus	Enrichment	TP53	3.83
22	Basal cell carcinoma 7	Enrichment	TP53	3.83
23	Anaplastic thyroid carcinoma	Enrichment	TP53	3.83
24	Ductal carcinoma in situ	Enrichment	TP53	3.83
25	Thyroid gland undifferentiated carcinoma	Enrichment	TP53	3.83
26	Small-cell carcinoma of the ovary of hypercalcemic type	Enrichment	TP53	3.83
27	Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype	Enrichment	TP53	3.83
28	Choroid plexus cancer	Enrichment	TP53	3.83
29	Pleomorphic xanthoastrocytoma	Enrichment	TP53	3.83
30	Colonic benign neoplasm	Enrichment	ATM, CHEK2	3.64
31	Lynch syndrome 1	Enrichment	ATM, CHEK2	3.54
32	Leukemia, chronic lymphocytic	Enrichment	ATM, TP53	3.54
33	Melanoma	Enrichment	CDKN2A, CHEK2	3.54
34	Adrenocortical carcinoma, hereditary	Enrichment	TP53	3.53
35	Cervical cancer	Enrichment	TP53	3.53
36	Lymphoma, hodgkin, classic	Enrichment	TP53	3.53
37	Congenital fibrosarcoma	Enrichment	TP53	3.53
38	Cervix carcinoma	Enrichment	TP53	3.53
39	Hodgkin's lymphoma	Enrichment	TP53	3.53
40	Pleomorphic rhabdomyosarcoma	Enrichment	TP53	3.53
41	Uterine corpus cancer	Enrichment	ATM, CHEK2	3.46
42	Familial colorectal cancer type x	Enrichment	ATM, CHEK2	3.46
43	Inherited cancer-predisposing syndrome	Enrichment	ATM, CDKN2A, CHEK2, TP53	3.45
44	Hereditary breast ovarian cancer syndrome	Enrichment	ATM, CHEK2, TP53	3.42
45	Myeloma, multiple	Enrichment	ATM, SGK1, TP53	3.40
46	Lip and oral cavity carcinoma	Enrichment	CDKN2A, TP53	3.38
47	Nasopharyngeal carcinoma	Enrichment	TP53	3.35
48	Atypical teratoid rhabdoid tumor	Enrichment	TP53	3.35
49	Anaplastic astrocytoma	Enrichment	TP53	3.35
50	Squamous cell carcinoma	Enrichment	TP53	3.35
51	Breast-ovarian cancer, familial 1	Enrichment	ATM, CHEK2	3.30
52	Small cell cancer of the lung	Enrichment	TP53	3.23
53	Thyroid cancer, nonmedullary, 1	Enrichment	TP53	3.23
54	Lung sarcomatoid carcinoma	Enrichment	TP53	3.23
55	Embryonal rhabdomyosarcoma	Enrichment	TP53	3.23
56	Renal cell carcinoma, nonpapillary	Enrichment	ATM, MTOR	3.18
57	Rhabdomyosarcoma 2	Enrichment	TP53	3.13
58	Lymphoma	Enrichment	TP53	3.13
59	Acute megakaryocytic leukemia	Enrichment	TP53	3.13
60	Gliosarcoma	Enrichment	ATM, TP53	3.12
61	Giant cell glioblastoma	Enrichment	ATM, TP53	3.07
62	Esophageal cancer	Enrichment	TP53	2.99
63	Squamous cell carcinoma, head and neck	Enrichment	TP53	2.99
64	Essential thrombocythemia	Enrichment	TP53	2.99
65	Gallbladder cancer	Enrichment	TP53	2.99
66	Diffuse large b-cell lymphoma	Enrichment	CHEK2, TP53	2.97
67	Glioma susceptibility 1	Enrichment	TP53	2.93
68	Lymphoma, non-hodgkin, familial	Enrichment	TP53	2.93
69	Endometrial cancer	Enrichment	ATM, CHEK2	2.88
70	Adult hepatocellular carcinoma	Enrichment	TP53	2.88
71	Primary hyperaldosteronism	Enrichment	TP53	2.88
72	Familial colorectal cancer	Enrichment	TP53	2.83
73	Myelodysplastic syndrome	Enrichment	TP53	2.79
74	Lung cancer susceptibility 3	Enrichment	TP53	2.69
75	Rhabdomyosarcoma	Enrichment	TP53	2.63
76	Proteus syndrome	Enrichment	AKT1	2.59
77	Hypoinsulinemic hypoglycemia with hemihypertrophy	Enrichment	AKT2	2.59
78	Accelerated tumor formation	Enrichment	MDM2	2.59
79	Lessel-kubisch syndrome	Enrichment	MDM2	2.59
80	Bone marrow failure syndrome 6	Enrichment	MDM4	2.59
81	Houge-janssens syndrome 4	Enrichment	PPP2R5C	2.59
82	Houge-janssens syndrome 2	Enrichment	PPP2R1A	2.59
83	Tumor predisposition syndrome 4	Enrichment	CHEK2	2.59
84	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2	Enrichment	AKT3	2.59
85	Cowden syndrome 6	Enrichment	AKT1	2.59
86	Endometrial serous adenocarcinoma	Enrichment	ATM	2.59
87	Leiomyosarcoma	Enrichment	CHEK2	2.59
88	Cdkn2a cancer predisposition	Enrichment	CDKN2A	2.59
89	Capillary hemangioma	Enrichment	AKT3	2.59
90	B-cell non-hodgkin lymphoma	Enrichment	ATM	2.59
91	Ppp2r1a-related neurodevelopmental disorder	Enrichment	PPP2R1A	2.59
92	Akt2-related familial partial lipodystrophy	Enrichment	AKT2	2.59
93	Lung cancer	Enrichment	CHEK2, PPP2R1B	2.51
94	Hepatoblastoma	Enrichment	TP53	2.51
95	Hepatocellular carcinoma	Enrichment	TP53	2.49
96	Diamond-blackfan anemia 1	Enrichment	TP53	2.47
97	Melanoma-astrocytoma syndrome	Enrichment	CDKN2A	2.29
98	Melanoma, cutaneous malignant 2	Enrichment	CDKN2A	2.29
99	Congenital heart defects, multiple types, 3	Enrichment	CHEK2	2.29
100	Cardiac valvular dysplasia, x-linked	Enrichment	ATM	2.29
101	Cebalid syndrome	Enrichment	MTOR	2.29
102	Senior-loken syndrome 7	Enrichment	AKT3	2.29
103	Melanoma-pancreatic cancer syndrome	Enrichment	CDKN2A	2.29
104	High grade glioma	Enrichment	ATM	2.29
105	Bardet-biedl syndrome 16	Enrichment	AKT3	2.29
106	T-cell prolymphocytic leukemia	Enrichment	ATM	2.29
107	Hao-fountain syndrome	Enrichment	USP7	2.29
108	Smith-kingsmore syndrome	Enrichment	MTOR	2.29
109	Houge-janssens syndrome 3	Enrichment	PPP2CA	2.29
110	Submucosal cleft palate	Enrichment	UBB	2.29
111	Cleft hard palate	Enrichment	UBB	2.29
112	Diamond-blackfan anemia	Enrichment	TP53	2.28
113	Leukemia, acute myeloid	Enrichment	TP53	2.23
114	Ataxia-telangiectasia	Enrichment	ATM	2.11
115	Polycythemia vera	Enrichment	ATM	2.11
116	Uvula, bifid	Enrichment	UBB	2.11
117	Cleft soft palate	Enrichment	UBB	2.11
118	Koolen-de vries syndrome	Enrichment	ATM	2.11
119	Dedifferentiated liposarcoma	Enrichment	MDM2	2.11
120	Well-differentiated liposarcoma	Enrichment	MDM2	2.11
121	Primary ovarian insufficiency	Enrichment	CHEK2, RICTOR	2.00
122	Megalencephaly-capillary malformation-polymicrogyria syndrome	Enrichment	AKT3	1.99
123	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1	Enrichment	AKT3	1.99
124	Focal cortical dysplasia, type ii	Enrichment	MTOR	1.99
125	Mantle cell lymphoma	Enrichment	ATM	1.99
126	Hemoglobin c disease	Enrichment	CHEK2	1.99
127	Isolated focal cortical dysplasia type ii	Enrichment	MTOR	1.99
128	Oculomotor apraxia	Enrichment	ATM	1.99
129	Glioblastoma	Enrichment	ATM	1.89
130	Wilms tumor 5	Enrichment	CHEK2	1.81
131	Clear cell renal cell carcinoma	Enrichment	ATM	1.81
132	Lung squamous cell carcinoma	Enrichment	CDKN2A	1.81
133	Megacolon	Enrichment	AKT3	1.75
134	Overgrowth syndrome	Enrichment	MTOR	1.75
135	Cowden syndrome	Enrichment	AKT1	1.64
136	Polymicrogyria	Enrichment	AKT3	1.59
137	Immune deficiency disease	Enrichment	ATM	1.55
138	Leukemia, acute lymphoblastic	Enrichment	CDKN2A	1.55
139	Meningioma	Enrichment	AKT1	1.52
140	Nk-cell enteropathy	Enrichment	CHEK2	1.48
141	Wilms tumor 1	Enrichment	CHEK2	1.42
142	Lynch syndrome	Enrichment	CHEK2	1.42
143	Rare genetic intellectual disability	Enrichment	MTOR	1.42
144	Melanoma, cutaneous malignant 1	Enrichment	CDKN2A	1.37
145	Precursor t-cell acute lymphoblastic leukemia	Enrichment	CDKN2A	1.24
146	Type 2 diabetes mellitus	Enrichment	AKT2	0.99
147	Complex neurodevelopmental disorder	Enrichment	PPP2CA	0.56

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

Regulation of TP53 Expression and Degradation

Pathway Network for Regulation of TP53 Expression and Degradation

Pathway network for the Regulation of TP53 Expression and Degradation SuperPath

Member Pathways for Regulation of TP53 Expression and Degradation

Pathways in the Regulation of TP53 Expression and Degradation SuperPath

Gene overlap in member pathways for Regulation of TP53 Expression and Degradation SuperPath

Associated Genes for Regulation of TP53 Expression and Degradation

Associated Disorders for Regulation of TP53 Expression and Degradation

Disorders associated with Regulation of TP53 Expression and Degradation SuperPath

STRING Interaction Network for Regulation of TP53 Expression and Degradation

Sources for Regulation of TP53 Expression and Degradation